RAPT Therapeutics’ (RAPT) “Buy” Rating Reiterated at HC Wainwright

RAPT Therapeutics (NASDAQ:RAPT)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $10.00 target price on the stock.

RAPT has been the subject of a number of other research reports. Piper Sandler downgraded shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $8.00 to $2.00 in a research note on Monday, November 11th. Stifel Nicolaus reaffirmed a “hold” rating and set a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Wells Fargo & Company dropped their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.29.

RAPT Therapeutics Price Performance

RAPT stock opened at $1.13 on Monday. RAPT Therapeutics has a 1 year low of $0.79 and a 1 year high of $10.05. The firm has a 50-day moving average of $1.25 and a 200 day moving average of $1.55. The company has a market cap of $39.50 million, a P/E ratio of -0.41 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last announced its earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69). On average, equities research analysts expect that RAPT Therapeutics will post -2.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On RAPT Therapeutics

Several large investors have recently bought and sold shares of RAPT. Medicxi Ventures Management Jersey Ltd purchased a new stake in shares of RAPT Therapeutics during the 4th quarter valued at about $35,316,000. TCG Crossover Management LLC bought a new position in RAPT Therapeutics during the fourth quarter valued at approximately $19,751,000. Orbimed Advisors LLC purchased a new stake in RAPT Therapeutics in the fourth quarter worth approximately $20,754,000. Foresite Capital Management VI LLC bought a new stake in RAPT Therapeutics in the 4th quarter worth approximately $19,750,000. Finally, RTW Investments LP purchased a new stake in RAPT Therapeutics during the 4th quarter valued at $18,587,000. 99.09% of the stock is currently owned by institutional investors.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.